Therapeutic Care of Angina, MI and CVA, Chapter 50

Question 1

1. Explain the non-pharmacological management of angina pectoris.

Question 2

2. Identify drug classes used for treating angina pectoris, myocardial infarction, and cerebrovascular accident.

Question 3

3. Explain the therapeutic action of each class of drug used in the treatment of angina, myocardial infarction, and cerebrovascular accident in relation to the pathophysiology of these conditions.

Question 4

4. List and understand additional drugs used in the TX of MI to manage symptoms (according to the FH preprinted orders and text)

Question 5

5. Describe the nurse’s role in the pharmacological management of clients who are receiving drugs used in the treatment of angina, myocardial infarction, and cerebrovascular accident.

Question 6

6. For each of the drug following drugs; nitroglycerin, atenolol, metoprolol, diltiazem, & reteplase, identify a trade name and explain its mechanism of action, therapeutic effects, and important adverse effects.

Question 7

7. Describe and explain, based on pharmacological principles, the rationale for nursing assessment, planning, and interventions (implementation) for clients with angina, myocardial infarction, and cerebrovascular accident.

Question 8

8. List and understand the drugs used to prevent and manage a CVA. (according to the FH preprinted orders and text)

Question 9

9. Describe the different types of nutritional therapy that may be needed post CVA.

Question 10

Understand how the mechanism of action of Nitroglycerin alleviates the symptoms of angina, plus the parameters of administration when taken in the home in response to chest pain.

Question 11

Know medications that are used in the acute TX of MI (thrombolytics in text and PP) the prevention of MI and TX of symptoms associated with an MI and their therapeutic action according to the FH guidelines for a STEMI in your Power Point.

Question 12

Understand Thrombolytic therapy as it relates to a Cerebrovascular accident.

Question 13

Know additional medications used in the prevention of a CVA and their therapeutic action in relation to a CVA.